Funding for this research was provided by:
U.S. Department of Veterans Affairs (I01BX003477, 11S-RCS-009, IK2 CX000525, 5T32MH019836-18, 1I01CX001276-01A2)
National Institute of Mental Health (1R21AG061367-01, R21MH102834, 1R01MH108826)
U.S. Army (U01MH087981)
National Institutes of Health (R01MH093500)
U.S. Department of Defense (HU0001-15-2-0004, W81XWH08-2-0159)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (916.11.086)
Text and Data Mining valid from 2020-03-14
Received: 31 October 2019
Accepted: 29 January 2020
First Online: 14 March 2020
Ethics approval and consent to participate
: This research was performed under the supervision and approval of US Department of Veterans Affairs human subjects review board. All participants supplied written informed consent.
: Not applicable
: FM participated in this study while also an NIMH-funded research post-doctoral fellow at Boston University/VA Boston Healthcare System, but is currently an employee of BlackThorn Therapeutics. MBS has in the past 3 years been a consultant for Actelion, Aptinyx, Bionomics, Dart Neuroscience, Healthcare Management Technologies, Janssen, Neurocrine Biosciences, Oxeia Biopharmaceuticals, Pfizer, and Resilience Therapeutics. In the past 3 years, RCK received support for his epidemiological studies from Sanofi Aventis; was a consultant for DataStat, Inc., Johnson & Johnson Wellness and Prevention, Sage Pharmaceuticals, Shire, Takeda; and served on an advisory board for the Johnson & Johnson Services Inc. Lake Nona Life Project. None of the remaining authors have any conflicts to disclose. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, the Department of Defense, NIMH, or the US government.